TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35855798

Group type: EXPERIMENTAL
Intervention: Gauze pressure bandage with 2% chlorhexidine gluconate (Group A)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Sterile cotton swab with 2% chlorhexanol gluconate (Group B)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 75% alcohol sterile cotton swab wipe for basic needle maintenance (Group C)
Number of subjects: 213
Study: 32580990

Group type: EXPERIMENTAL
Intervention: Orally administered prednisolone 50 mg per day for up to 3 days, tapering to cessation over 10 days, in addition to guideline advice.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Orally administered prednisolone
Number of subjects: 200
Study: 33231373

Group type: EXPERIMENTAL
Intervention: Risdiplam (EVRYSDI®)
Number of subjects: 245
Study: 35840905

Group type: EXPERIMENTAL
Intervention: CAMRY EH101 dynamometer
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Jamar dynamometer
Number of subjects: 1064
Study: 33853550

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) at escalating doses starting from 6 Gy × 2 weekly fractions to a maximum of 6 Gy × 5 weekly fractions (dose level 4)
Number of subjects: 48
Study: 33384335

Group type: EXPERIMENTAL
Intervention: First-line infliximab (FL-IFX) - 5 mg/kg infusions at weeks 0, 2, 6, 14, and 22
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment - exclusive enteral nutrition (EEN) or oral prednisolone (1 mg/kg, max 40 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: First-line infliximab (FL-IFX) on azathioprine monotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment on azathioprine monotherapy
Number of subjects: 100
Study: 33398094

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) with steroids
Number of subjects: 81

Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 81
Study: 32473355

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180-mg loading dose followed by 90-mg twice daily maintenance for 1 year)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Clopidogrel (600-mg loading dose followed by 75-mg/d maintenance for 1 year)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 508

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 508
Study: 33627763

Group type: EXPERIMENTAL
Intervention: Rifaximin (non-absorbable antibiotic) for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study: 32961461

Group type: EXPERIMENTAL
Intervention: Breastfeeding education program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 104
Study: 35229675

Group type: EXPERIMENTAL
Intervention: Gross motor skill-based exercise intervention (one weekly session for 25 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 32342619

Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg/day for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33949268

Group type: EXPERIMENTAL
Intervention: Palliative care interventions (specific interventions not detailed)
Number of subjects: 0
Study: 36430041

Group type: EXPERIMENTAL
Intervention: Forest stay
Number of subjects: 39

Group type: COMPARATOR
Intervention: Field stay
Number of subjects: 39
Study: 32950748

Group type: EXPERIMENTAL
Intervention: 600 mg intravenous mirikizumab
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous mirikizumab
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 200 mg subcutaneous mirikizumab (maintenance therapy)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (induction phase)
Number of subjects: 84
Study: 33257421

Group type: EXPERIMENTAL
Intervention: Highest quartile of SD of HbA1C
Number of subjects: 3560

Group type: EXPERIMENTAL
Intervention: Highest quartile of SD of FPG
Number of subjects: 3560
Study: 34973357

Group type: EXPERIMENTAL
Intervention: KT FIX Plus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study: 33047340

Group type: EXPERIMENTAL
Intervention: Risk-stratified, population management dashboard combined with practice facilitation
Number of subjects: 146826

Group type: COMPARATOR
Intervention: Stepped-wedge controls
Number of subjects: 146826
Study: 36055633

Group type: EXPERIMENTAL
Intervention: Lateral occlusion of the uterine artery (LA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no lateral occlusion)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 33836310

Group type: EXPERIMENTAL
Intervention: Thrice-weekly PRT plus impact exercise training
Number of subjects: 172

Group type: COMPARATOR
Intervention: Non-exercising
Number of subjects: 172
Study: 34878329

Group type: EXPERIMENTAL
Intervention: Active neurofeedback (NF) of an addiction-related brain region
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham neurofeedback (NF)
Number of subjects: 54
Study: 32898029

Group type: EXPERIMENTAL
Intervention: Training on new guidelines for return to activity after concussion
Number of subjects: 21
Study: 33431967

Group type: EXPERIMENTAL
Intervention: 15% CO2 treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-CO2 concentration formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaOH treatment (to correct medium acidification)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knockdown of H+-sensing G protein-coupled receptor 65
Number of subjects: 0
Study: 32500151

Group type: EXPERIMENTAL
Intervention: Tissue-grouped BMI-associated genetic instruments
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Randomly sampled sets of 100 or 200 BMI-associated genetic variants
Number of subjects: 634
Study: 35090363

Group type: EXPERIMENTAL
Intervention: 10 mg psilocybin
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 33504555

Group type: EXPERIMENTAL
Intervention: Immunotherapy (dinutuximab + GM-CSF + IL2)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Isotretinoin only
Number of subjects: 226
Study: 35432566

Group type: EXPERIMENTAL
Intervention: ZuoJin Pill (ZJP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Marzulene-S granule
Number of subjects: 68
Study: 33405304

Group type: EXPERIMENTAL
Intervention: Collaborative care with motivational interviewing (CCMI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attention control psychoeducation (ACP)
Number of subjects: 100
Study: 34422864

Group type: EXPERIMENTAL
Intervention: Peer-led pain management program
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 262
Study: 33303110

Group type: EXPERIMENTAL
Intervention: 20 minutes of treadmill walking (60-70% heart rate max)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Restful reading (non-exercise control)
Number of subjects: 116
Study: 35858941

Group type: EXPERIMENTAL
Intervention: Bonded spurs and posterior build-ups
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bonded spurs alone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 49
Study: 34032040

Group type: EXPERIMENTAL
Intervention: Locking plate external fixation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditional open reduction with plate internal fixation
Number of subjects: 92
Study: 36341753

Group type: EXPERIMENTAL
Intervention: More intensive treatment (systolic blood pressure target <120 mm Hg)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Less intensive treatment (systolic blood pressure target 140-180 mm Hg)
Number of subjects: 821
Study: 32205376

Group type: EXPERIMENTAL
Intervention: Carrageenan-based personal lubricant (self-applied anal microbicide gel)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo (self-applied placebo gel)
Number of subjects: 380
Study: 35834200

Group type: EXPERIMENTAL
Intervention: Self-interest prompt
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Prosocial prompt
Number of subjects: 591
Study: 33372717

Group type: EXPERIMENTAL
Intervention: Teacher-delivered school mental health intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implementation science framework
Number of subjects: 0
Study: 35351805

Group type: EXPERIMENTAL
Intervention: JUUL menthol e-cigarettes
Number of subjects: 64

Group type: COMPARATOR
Intervention: non-menthol e-cigarettes
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: menthol e-cigarettes
Number of subjects: 64
Study: 33761083

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) sessions delivered by social insurance caseworkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) sessions
Number of subjects: 0
Study: 34993863

Group type: EXPERIMENTAL
Intervention: Hepatitis App (mobile application delivering interactive video education on viral hepatitis in English, Cantonese, Mandarin, or Vietnamese, along with Provider Alert and Provider Panel Notification)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Comparison group (mobile application delivering nutrition and physical activity education and Provider Panel Notification)
Number of subjects: 452
Study: 34054112

Group type: EXPERIMENTAL
Intervention: lumateperone 42 mg
Number of subjects: 1073

Group type: COMPARATOR
Intervention: risperidone 4 mg
Number of subjects: 1073

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1073
Study: 32492181

Group type: EXPERIMENTAL
Intervention: Experimental analogues depicting completed or potential sexual assault in various formats (written, audio, video, virtual simulation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Experimental analogues
Number of subjects: 17
Study: 35349526

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (30 minutes using a cycle ergometer)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine HD without exercise (control)
Number of subjects: 20
Study: 34108140

Group type: EXPERIMENTAL
Intervention: Proximate WBC DNA methylation in ERCC1
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Distant WBC DNA methylation in ERCC1
Number of subjects: 594
Study: 35995953

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 471

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 471
Study: 32505126

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 32324634

Group type: EXPERIMENTAL
Intervention: Improv course (15-hour course to teach interprofessional empathy)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Improv course
Number of subjects: 86
Study: 35770246

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sudarshan Kriya Yoga (SKY)
Number of subjects: 59
Study: 32222767

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 86
Study: 35807783

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (50,000 IU on the first and eighth days)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 IU)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No cholecalciferol supplementation (Control Group)
Number of subjects: 129
Study: 35357058

Group type: EXPERIMENTAL
Intervention: Itopride (100 mg t.i.d.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Itopride in overlapping PDS/EPS subgroup (n = 55)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Itopride in pure PDS subgroup (n = 45)
Number of subjects: 100
Study: 33212341

Group type: EXPERIMENTAL
Intervention: Whole milk powder (WMP)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nonfat dry milk (NFDM)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hydrated powders
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: NFDM and WMP
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hydrated NFDM and WMP
Number of subjects: 3
Study: 35967112

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 867

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 867
Study: 34615779

Group type: EXPERIMENTAL
Intervention: TurmNova® lozenges containing turmeric extract 100 mg and clove oil 10 mg three times daily for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intralesional infiltration of 2 mL dexamethasone (4 mg/mL) + hyaluronidase 1500 IU dissolved in 0.5 mL of 2% lignocaine twice a week for 3 months
Number of subjects: 80
Study: 32978121

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 208
Study: 34755569

Group type: EXPERIMENTAL
Intervention: Acupuncture (4 sessions on days 1/2/4/6 for 1 week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (pharmacotherapy for pain management without acupuncture)
Number of subjects: 30
Study: 34933975

Group type: EXPERIMENTAL
Intervention: We Care Solar Suitcase (solar electric system providing lighting and power)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-intervention
Number of subjects: 30
Study: 35400227

Group type: EXPERIMENTAL
Intervention: Burpee Interval Training (BIT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vigorous Intensity Continuous Training (VICT)
Number of subjects: 18
Study: 35973185

Group type: EXPERIMENTAL
Intervention: High total/low simple carbohydrate diet for 9 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: High total/high simple carbohydrate diet (control group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: All carbohydrate modification groups
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: High total/low simple carbohydrate diet
Number of subjects: 98
Study: 35005793

Group type: EXPERIMENTAL
Intervention: 0.06 U/min oxytocin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 0.12 U/min oxytocin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 0.24 U/min oxytocin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 0.36 U/min oxytocin
Number of subjects: 124
Study: 33302751

Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants
Number of subjects: 7642
Study: 33829609

Group type: EXPERIMENTAL
Intervention: Axitinib and carotuximab (TRC105) combination therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Axitinib monotherapy
Number of subjects: 150
Study: 33056965

Group type: EXPERIMENTAL
Intervention: Retinalamin treatment course every 6 months
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study: 35345524

Group type: EXPERIMENTAL
Intervention: Health education combined with personalized psychological nursing intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: Routine education and routine examination (Control)
Number of subjects: 170
Study: 33762716

Group type: EXPERIMENTAL
Intervention: Conventional sequence of epirubicin/cyclophosphamide and docetaxel
Number of subjects: 311

Group type: COMPARATOR
Intervention: Reverse sequence of epirubicin/cyclophosphamide and docetaxel
Number of subjects: 311
Study: 33138109

Group type: COMPARATOR
Intervention: ILCOR
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: CCR
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Arnsberg
Number of subjects: 286
Study: 36653090

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor (evolocumab) 140 mg subcutaneous injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor (evolocumab)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32354299

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial corticosteroid injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blind subacromial corticosteroid injection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Ultrasound and Blind)
Number of subjects: 30
Study: 32992440

Group type: EXPERIMENTAL
Intervention: 0.9 g·kg·FFM−1 GLN (HIGH)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.6 g·kg·FFM−1 GLN (MED)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.3 g·kg·FFM−1 GLN (LOW)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14
Study: 35337288

Group type: COMPARATOR
Intervention: Bilateral tDCS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 48
Study: 36126132

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SeQuent SCB, 4 μg/mm²)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (SeQuent Please, 3 μg/mm²)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both SCB and PCB
Number of subjects: 101
Study: 35545431

Group type: EXPERIMENTAL
Intervention: Within Our Reach curriculum (12 hours)
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1418
Study: 33710659

Group type: EXPERIMENTAL
Intervention: Video‐to‐home cognitive‐behavioral therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clinic‐based treatment as usual
Number of subjects: 90
Study: 32603554

Group type: EXPERIMENTAL
Intervention: IgG4-related sclerosing cholangitis (IgG4-SC) patients
Number of subjects: 1045
Study: 35799473

Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 172
Study: 33600846

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 136
Study: 34985003

Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable-polymer sirolimus-eluting Orsiro stent (O-SES)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polymer-free biolimus-A9-eluting BioFreedom stent (BF-BES)
Number of subjects: 80
Study: 33728806

Group type: EXPERIMENTAL
Intervention: Individualized prediction model for COVID-19 deterioration
Number of subjects: 276
Study: 32538762

Group type: EXPERIMENTAL
Intervention: Dezocine and ropivacaine infiltration anesthesia
Number of subjects: 92
Study: 35110636

Group type: EXPERIMENTAL
Intervention: High-volume Continuous Exercise (CE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lower-volume Intermittent exercise of Long bouts with Long interval (ILL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lower-volume Intermittent exercise of Long bouts with Short interval (ILS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lower-volume Intermittent exercise of Short bouts with Short interval (ISS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 20
Study: 34003285

Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy+ (CFT+) with psychologist support and option of additional usual care
Number of subjects: 176

Group type: COMPARATOR
Intervention: Interdisciplinary pain management pathway (usual care)
Number of subjects: 176
Study: 36700035

Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain, orally administrated at 1.0×10^10 colony-forming units once daily for 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34107173

Group type: EXPERIMENTAL
Intervention: Flonoxin 400 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Avelox 400 mg
Number of subjects: 30
Study: 35805767

Group type: EXPERIMENTAL
Intervention: Dental care, anticipatory guidance on oral health and dietary intake, motivational interviewing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies for participant engagement
Number of subjects: 0
Study: 34657222

Group type: EXPERIMENTAL
Intervention: Ampreloxetine 5 mg and 10 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ampreloxetine (median dose 15 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ampreloxetine (median dose 10 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ampreloxetine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Withdrawal after ampreloxetine treatment
Number of subjects: 34
Study: 34051103

Group type: EXPERIMENTAL
Intervention: Ultrasound guided SGB
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fluoroscopic guided SGB
Number of subjects: 10
Study: 35685430

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33290938

Group type: EXPERIMENTAL
Intervention: Narrative exposure therapy for forensic offender rehabilitation (FORNET)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 27
Study: 34800568

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unstructured Psychotherapy (Talking Control: TC)
Number of subjects: 38
Study: 32066559

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 110
Study: 35916246

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 97

Group type: COMPARATOR
Intervention: Online training
Number of subjects: 97
Study: 32488320

Group type: EXPERIMENTAL
Intervention: Peer review process using a web-based checklist with nine rating categories and dichotomous response format (deficiency/no deficiency)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall quality rating of medical reports
Number of subjects: 30
Study: 32271840

Group type: EXPERIMENTAL
Intervention: Fortetropin®
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fortetropin® vs Placebo
Number of subjects: 100
Study: 35325298

Group type: EXPERIMENTAL
Intervention: ProDisc-C
Number of subjects: 120

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 120
Study: 33610175

Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1% at 30 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1% at 40 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1% at 50 mg
Number of subjects: 45